EE427 Annual Cost Savings From the Use of Empagliflozin Over DPP4I in Select Asia-Pacific Countries – Estimates Based on the Emprise East Asia Study

Abstract

The recently published findings of the EMPRISE East Asia study that looked at patients with type 2 diabetes mellitus (T2DM) in Japan, South Korea, and Taiwan demonstrated that empagliflozin treatment was associated with lower inpatient care needs and other healthcare resource utilization (HRU) than dipeptidyl peptidase-4 inhibitors (DPP4i) in routine clinical practice. The aim of this analysis was to estimate the annual costs savings arising from the reduction in the rates of HRU arising from the use of empagliflozin over DPP4i in select Asia-Pacific countries (Australia, Indonesia, Malaysia, Philippines, Thailand and Vietnam) based on the EMPRISE East Asia study findings.